Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

被引：21

作者：

Einsele, H. ^{[1
]}

Knop, S. ^{[1
]}

Vogel, M. ^{[2
]}

Mueller, J. ^{[3
]}

Kropff, M. ^{[4
]}

Metzner, B. ^{[5
]}

Langer, C. ^{[6
]}

Sayer, H. ^{[7
]}

Jung, W. ^{[8
]}

Duerk, H. A. ^{[9
]}

Salwender, H. ^{[10
]}

Wandt, H. ^{[11
]}

Bassermann, F. ^{[12
]}

Gramatzki, M. ^{[13
]}

Roesler, W. ^{[14
]}

Wolf, H-H ^{[15
]}

Brugger, W. ^{[16
]}

Engelhardt, M. ^{[17
]}

Fischer, T. ^{[18
]}

Liebisch, P. ^{[6
]}

Straka, C. ^{[19
]}

机构：

[1] Julius Maximilians Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Janssen Cilag GmbH, Neuss, Germany

[3] Acromion GmbH, Frechen, Germany

[4] Univ Klinikum Munster, Munster, Germany

[5] Klinikum Oldenburg Klin Onkol & Hamatol, Oldenburg, Germany

[6] Univ Klinikum Ulm, Zentrum Innere Med, Ulm, Germany

[7] Univ Hosp Jena, Jena, Germany

[8] Onkol Univ Med Gottingen, Gottingen, Germany

[9] St Marien Hosp Hamm Knappenstr, Hamm, Germany

[10] Asklepios Klin Altona, Hamburg, Germany

[11] Med Klin 5 Hamatol & Onkol, Nurnberg, Germany

[12] Tech Univ Munich, Med Klin, Munich, Germany

[13] Univ Klinikum Schleswig Holstein, Kiel, Germany

[14] Univ Klinkum Erlangen, Erlangen, Germany

[15] Univ Hosp Halle, Halle, Saale, Germany

[16] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany

[17] Univ Freiburg, Freiburg, Germany

[18] Otto von Guericke Univ, Magdeburg, Germany

[19] Schon Klin Starnberger See, Berg, Germany

来源：

LEUKEMIA | 2017年 / 31卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; INDUCTION; THERAPY; PHASE-3;

D O I：

10.1038/leu.2017.83

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1463 / 1466

页数：5

共 50 条

[21] Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study
Gordan, Lucio
Tan, Carlyn Rose
Vescio, Robert
Ye, Jing Christine
Schinke, Carolina
Medhekar, Rohan
Fu, Alex
Lafeuille, Marie-Helene
Thompson-Leduc, Philippe
Khare, Vipin
Reitan, John
Milkovich, Gary
Kaila, Shuchita
Davies, Faith
Usmani, Saad
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S98 - S98
[22] BORTEZOMIB CONSOLIDATION FOLLOWING ASCT FOR MULTIPLE MYELOMA (MM) IMPROVES RESPONSE DEPTH, WITH ACCEPTABLE TOXICITY AND PRESERVED QUALITY OF LIFE
Rabin, N.
Nicholas, C.
Owen, R.
Popova, B.
Schofield, O.
Rawston, A.
de Tute, R.
Lyons-Lewis, J.
Moore, S.
Hughes, D.
Yong, K.
HAEMATOLOGICA, 2015, 100 : 515 - 516
[23] Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study
Gordan, Lucio
Tan, Carlyn Rose
Vescio, Robert
Ye, Jing Christine
Schinke, Carolina
Medhekar, Rohan
Fu, Alex Z.
Lafeuille, Marie-Helene
Thompson-Leduc, Philippe
Khare, Vipin
Reitan, John
Milkovich, Gary
Kaila, Shuchita
Davies, Faith
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S502 - S502
[24] Daratumumab Improves Progression-Free Survival in Relapsed/Refractory Myeloma
Schuyler, Devon
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (11) : 915 - 915
[25] Daratumumab improves depth of response and progression free survival in transplant-ineligible, high-risk, newly diagnosed multiple myeloma (NDMM)
Jakubowiak, Andrzej
Kumar, Shaji
Medhekar, Rohan
Pei, Huiling
Lefebvre, Patrick
Kaila, Shuchita
He, Jianming
Lafeuille, Marie-Helene
Cortoos, Annelore
Londhe, Anil
Mavros, Panagiotis
Lin, Thomas
Usmani, Saad Z.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S2 - S2
[26] Bevacizumab prolongs progression-free survival but not overall survival in newly diagnosed glioblastoma
Hemi Malkki
Nature Reviews Neurology, 2014, 10 (4) : 179 - 179
[27] Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial
Jackson, Graham H.
Davies, Faith E.
Pawlyn, Charlotte
Cairns, David A.
Striha, Alina
Collett, Corinne
Waterhouse, Anna
Jones, John R.
Kishore, Bhuvan
Garg, Mamta
Williams, Cathy D.
Karunanithi, Kamaraj
Lindsay, Jindriska
Wilson, Jamie N.
Jenner, Matthew W.
Cook, Gordon
Kaiser, Martin F.
Drayson, Mark T.
Owen, Roger G.
Russell, Nigel H.
Gregory, Walter M.
Morgan, Gareth J.
LANCET HAEMATOLOGY, 2019, 6 (12): : E616 - E629
[28] Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
Syed, Yahiya Y.
DRUGS, 2017, 77 (13) : 1473 - 1480
[29] Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT
Yahiya Y. Syed
Drugs, 2017, 77 : 1473 - 1480
[30] Recovery of policlonal immunoglobulins as a predictor factor of increased progression-free survival and overall survival in patients with multiple myeloma ineligible for ASCT
Davila, Julio
Gonzalez-Calle, Veronica
Puig, Noemi
Barez, Abelardo
Escalante, Fernando
Rosa, Lopez
Maria Alonso, Jose
Aguilar, Carlos
Garcia-Mateo, Aranzazu
Contreras, Teresa
Labrador, Jorge
Aguilera, Carmen
Garcia de Coca, Alfonso
Hernandez, Roberto
Mateos, Maria-Victoria
Ocio, Enrique M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E176 - E177

← 1 2 3 4 5 →